46th week of 2010 patent applcation highlights part 35 |
Patent application number | Title | Published |
20100291080 | COMPOSITIONS AND METHODS FOR TISSUE REPAIR - The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and grow, thereby facilitating the repair and/or regeneration of the injured tissue. | 2010-11-18 |
20100291081 | RAGE FUSION PROTEINS - The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycation endproducts receptor (RAGE). | 2010-11-18 |
20100291082 | ANTIGEN PRESENTING CELL TARGETED ANTI-VIRAL VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 2010-11-18 |
20100291083 | Novel Analgesic Treatment with Prolonged Effect - Use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA, in particular capable of blocking the biological activity of TrkA, for the preparation of a medicament for treating and/or preventing chronic pain. | 2010-11-18 |
20100291084 | USE OF IL-23 ANTAGONISTS FOR TREATMENT OF INFECTION - Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections. | 2010-11-18 |
20100291085 | ANTIBODIES TO OX-2/CD200 AND USES THEREOF IN INHIBITING IMMUNE RESPONSES - This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival. | 2010-11-18 |
20100291086 | USE OF ESTROGEN AND ANDROGEN BINDING PROTEINS IN METHODS AND COMPOSITIONS FOR TREATING GYNAECOLOGICAL CANCERS - The present invention provides a polypeptide comprising an estrogen or androgen binding region, the binding region capable of binding to an estrogen or androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available estrogen or androgen is decreased. The invention also provides for the treatment or prevention of cancers such as ovarian cancer, breast cancer and endometrial cancer using the polypeptides. | 2010-11-18 |
20100291087 | METHOD OF TREATING FIBRPROLIFERATIVE DISORDERS - Materials and Methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone. | 2010-11-18 |
20100291088 | IL-18 BINDING PROTEINS - The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental. | 2010-11-18 |
20100291089 | LIGAND OF REGULATING IMMUNE RESPONSE, AND USE THEREOF IN TREATING AN IMMUNE RESPONSE-RELATED DISEASE - The present invention relates to a ligand to regulate immune response, i.e., PACAP27 which is one of pituitary adenylate cyclase-activating polypeptides and Serum amyloid A (SAA), and their novel use in treating or preventing diseases associated with immune response. More specifically, the present invention relates to a complex of PACAP27-FPRL1 having a regulatory effect on immune response, and a use thereof in regulating immune response. In another aspect, the present invention relates to a complex of SAA and FPRL1, and a use thereof in inhibiting synoviocyte hyperplasia and angiogenesis and treating or preventing inflammatory diseases including Rheumatoid arthritis (RA). | 2010-11-18 |
20100291090 | Prion Protein as a Receptor for Amyloid-Beta Oligomers - The invention provides methods of inhbiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating Alzheimer's disease by administration of a PrPc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinittions, as well as methods of identifying molecules that could function as PrP | 2010-11-18 |
20100291091 | CANCER ASSOCIATED GENE LY6K - LY6K is identified herein as a potential biomarker useful for the diagnosis of cancer, such as lung and esophageal cancers, as well as for the prognosis of patients with these diseases. As discussed in detail herein, LY6K is specifically over-expressed in most lung and esophageal cancer tissues examined, and is elevated in the sera of a large proportion of patients with these tumors. Accordingly, LY6K may be used in combination with other tumor markers to significantly improve the sensitivity of cancer diagnosis. LY6K may be used in the treatment of ESCC cells, as demonstrated by the fact that small interfering RNAs (siRNAs) of LY6K suppressed growth of the cancer cells. Moreover, the LY6K molecule is also a likely candidate for development of novel therapeutic approaches, such as antibody therapy. | 2010-11-18 |
20100291092 | COMPOSITIONS AND METHODS FOR DETECTION, PREVENTION, AND TREATMENT OF ANTHRAX AND OTHER INFECTIOUS DISEASES - Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against | 2010-11-18 |
20100291093 | ANTIBODY-MEDIATED DISRUPTION OF QUORUM SENSING IN BACTERIA - The invention provides an immunogenic molecular entity, a supramolecular assembly, and an antibody that can be used to inhibit Gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a Gram-positive bacterial infection. The invention also provides methods of inhibiting Gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a Gram-positive bacterial infection. | 2010-11-18 |
20100291094 | NUCLEIC ACID ENCODING 238P1B2 USEFUL IN DETECTING CANCER - A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization. | 2010-11-18 |
20100291095 | IDENTIFICATION OF A CONSERVED REGION OF PLASMODIUM FALCIPARUM MSP3 TARGETED BY BIOLOGICALLY ACTIVE ANTIBODIES - Antigenic and immunogenic determinants of Merozoite surface protein 3 (MSP3). Antigenicity and functional assays identified a 68-amino acid conserved domain of MSP3 as a target of biologically active antibodies. A peptide comprising amino acid residues 184-251 of SEQ ID NO: 2, may also be employed as may peptides consisting of different combinations of the MSP3 a, b, c, d, e and f peptides. Particular non-overlapping or overlapping segments of MSP3 a, b, c, d, e and f peptides may also be used. The various overlapping segments and nonoverlapping segments among the different MSP3 peptides are shown in FIG. | 2010-11-18 |
20100291096 | THERAPEUTIC PEPTIDES FOR THE TREATMENT OF METATSTATIC CANCER - Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect. | 2010-11-18 |
20100291097 | MONOCLONAL ANTIBODY - The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly those ocular diseases associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system. | 2010-11-18 |
20100291098 | Diabetic nephropathy therapies - The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided. | 2010-11-18 |
20100291099 | NOVEL 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 AND 32222 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 2010-11-18 |
20100291100 | Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions - The present invention provides genes encoding novel microbial proteins (i.e., for example, exosporium genes and proteins) that mediate the attachment of microbial spores to surfaces. Specific fragments of these microbial spore proteins may be utilized to inhibit the attachment of microbial spores to surfaces, thereby providing an infection control agent. The invention provides recombinant expression vectors comprising genes encoding exosporium proteins, as well as host cells containing these expression vectors. Further provided herein are screening methods for identifying infection control compositions comprising exosporium proteins that inhibit bacterial spore attachment to either bodily tissues or solid surfaces. Additionally, the invention provides for the use of nucleic acid inhibitors of exosporium protein expression by hybridizing with nucleic acid sequences encoding exosporium proteins as well as with exosporium mRNA. The invention further describes monoclonal and polyclonal antibodies having affinity for exosporium proteins. | 2010-11-18 |
20100291101 | NEW ANTI-IRC85 MONOCLONAL ANTIBODY; AND COMPOSITION COMPRISING THE SAME FOR PREVENTING AND TREATING TUBERCULOSIS OR ENTERITIS DISEASE; AND THE USE THEREOF - The present invention provides the novel anti-IRC85 monoclonal antibody specifically binding with IRC85 and it showed potent effect in removing the infected/phagocytosed bacteria from THP-I, a monocytic cell that expresses human IRC85 and is infected with | 2010-11-18 |
20100291102 | Therapeutic Agent - Anti-HLA and other antibodies are present in goat serum after injection of HIV antigenic material, and form the basis for a most surprisingly effective treatment of HIV, multiple sclerosis and other conditions. | 2010-11-18 |
20100291103 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS - The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis. | 2010-11-18 |
20100291104 | BORDETELLA OUTER-MEMBRANE PROTEIN ANTIGENS AND METHODS OF MAKING AND USING THE SAME - An isolated protein or peptide selected from the group consisting of | 2010-11-18 |
20100291105 | AGENT FOR THE TREATMENT OF MALIGNANT DISEASES - The invention proposes an agent for the treatment of tumor diseases, for example the multiple myeloma, said agent acting upon NK cells through the activation of an anti-tumor immune response after stimulation of the NKp30 receptor and the natural cytotoxicity receptors (NCR). Said agent contains in an acceptable carrier material a physiologically effective amount of the BAT3 protein and/or BAT3/antiCD138 or BAT3-specific antibodies or derivatives of these substances. According to the principle identical to that adopted for the BAT3/anti-CD138 protein the invention may also be used for the treatment of CD138-negative tumors. For this purpose the antiCD138 component with an antibody fragment is replaced by an optional tumor antigen and the respective agent is used for the therapy of tumors expressing this tumor antigen. Moreover, the invention also proposes the use of recombinant BAT3 protein or a BAT3 fragment without anti-body-based fusion component for the treatment of malignant diseases by activating NKp30 and NCR on NK cells. Finally, the invention relates to the use of BAT3 cDNA for in-vivo and/or ex-vivo introduction of BAT3 into tumor cells leading to an improved detection by NK cells in the immunotherapy of malignant diseases. | 2010-11-18 |
20100291106 | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C3B - The present invention relates to antibodies and antigen binding fragments thereof that bind to both human and cynomolgus complement protein C3b, as well as compositions and methods of use thereof. | 2010-11-18 |
20100291107 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR - The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor. | 2010-11-18 |
20100291108 | ANTIBODIES TO IREM-1 - Anti-IREM-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind IREM-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of IREM-1. | 2010-11-18 |
20100291109 | TLR AGONIST (FLAGELLIN)/CD40 AGONIST/ANTIGEN PROTEIN AND DNA CONJUGATES AND USE THEREOF FOR INDUCING SYNERGISTIC ENHANCEMENT IN IMMUNITY - Fusion proteins and DNA conjugates are disclosed which contain a TLR/CD40/agonist and optional antigen combination. The use of these protein and DNA conjugates as immune adjuvants and as vaccines for treatment of various chronic diseases such as HIV infection is also provided. | 2010-11-18 |
20100291110 | Compositions and Methods for Regulating NK Cell Activity - The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects. | 2010-11-18 |
20100291111 | Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell Proliferation - The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents. | 2010-11-18 |
20100291112 | Recombinant, Single-Chain, Trivalent Tri-Specific or Bi-Specific Antibody Derivatives - The present invention relates to a nucleic acid molecule encoding a polypeptide, wherein the polypeptide comprises (a) a first immunoglobulin domain comprising a V | 2010-11-18 |
20100291113 | Treatment of Proliferative Disorders Using Antibodies to PSMA - Methods of treating cancer in a patient are provided. In some embodiments the method comprises administering an antibody that is capable of binding to the extracellular domain of PSMA. In some embodiments, the method comprises restricting folate intake by the patient. Methods of monitoring cancer therapy are provided as well as kits for treating cancer and kits for monitoring cancer therapy. | 2010-11-18 |
20100291114 | Crystal structures and methods using same - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the identification and uses of said modulators. | 2010-11-18 |
20100291115 | PHARMACEUTICAL COMPOSITION FOR THE SUBLINGUAL ADMINISTRATION OF VACCINES, METHOD FOR THE PREPARATION OF THE SAME AND USES THEREOF - The subject of the present invention is a pharmaceutical composition for the sublingual administration of vaccines, a method for its preparation and the use thereof for modulating the absorption rate and substantially improving its effectiveness and safety. Said sublingual composition is applicable both to immunizing vaccines, which are employed against infections, and to desensitising vaccines, which have allergies as therapeutic indication. | 2010-11-18 |
20100291116 | MICROPARTICLE COMPRISING CROSS-LINKED POLYMER - Microparticle comprising a cross-linked polymer comprising (a) a cross-linker comprising two or more radically polymerizable groups, preferably selected from the group consisting of alkenes, sulfhydryl (SH), thioic, unsaturated esters, unsaturated urethanes, unsaturated ethers, and unsaturated amides; (b) a monofunctional reactive diluent comprising maximum one unsaturated C—C bond represented by the formula R | 2010-11-18 |
20100291117 | METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASES - The invention provides methods for the ex-vivo expansion of CD4+CD25+ Tregs. The invention provides a method for producing ex vivo expanded Tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens. Additionally, the ex vivo expanded Tregs may provide treatment for inflammatory/automimmune diseases. | 2010-11-18 |
20100291118 | Class of Gamma Delta T Cells Activators and Use Thereof - The present invention relates to a new class of compounds having γδ T cells activating properties of Formula (I), | 2010-11-18 |
20100291119 | Alpha B crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis - The present invention discloses the first medical use of alpha B crystallin or derivatives thereof in the field of auto-immune diseases, particularly multiple sclerosis. It also discloses diagnostic methods and tools therefor based upon alpha B crystallin for the detection of multiple sclerosis. Human alpha B crystallin is a known protein in itself, known to be present in the eye and in small amounts in the white matter of the nerve system, which is affected by multiple sclerosis. By using a novel and inventive approach to test for ability to induce auto-immunity, alpha B crystallin has been shown by the present invention to be an important auto-antigen. Such methods are also part of the invention. | 2010-11-18 |
20100291120 | PEPTIDES REGULATING THE SURFACE EXPRESSION OF THE T CELL RECEPTOR - The present invention is related to a peptide comprising an amino acid sequence according to SEQ. ID. No 1. | 2010-11-18 |
20100291121 | Tumour-Specific Animal Proteins - CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal, breast, and lung cancers, autoimmune diseases, and related conditions. | 2010-11-18 |
20100291122 | METHOD FOR ENHANCING IMMUNE RESPONSE WITH PEPTIDE - An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid β peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid β peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine. | 2010-11-18 |
20100291123 | T Cell Receptor CDR3 Sequences and Methods for Detection - The present invention relates generally to the field of treating autoimmune diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA) and others. Methods of treating and monitoring an autoimmune disease by utilizing T-cell receptors peptides are disclosed. Nucleic acid and peptide sequences of T-cell receptors found in a population of MS patients are also disclosed. | 2010-11-18 |
20100291124 | Extracellular serine protease - The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas. | 2010-11-18 |
20100291125 | ETA-1 GENE AND METHODS FOR USE - The present application relates to osteopontin (Eta-1) polypeptides, nucleic acids that encode Eta-1, antibodies that specifically bind to Eta-1, and methods for enhancing an immune response in an animal. | 2010-11-18 |
20100291126 | PROTEIN SHOWING ENHANCED EXPRESSION IN CANCER CELLS - A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization. | 2010-11-18 |
20100291127 | TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES - The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules. | 2010-11-18 |
20100291128 | NOVEL COMPOSITIONS AND VACCINES AGAINST INFLUENZA A AND INFLUENZA B INFECTIONS - Novel models of interactions of the Nonstructural Protein of influenza A and influenza B viruses (NS1A and NS1B, respectively) with dsRNA are presented. On the basis of the models, novel recombinant viruses and vaccines against influenza A and influenza B viruses are provided. | 2010-11-18 |
20100291129 | Norovirus and sapovirus antigens - Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described. The immunogenic compositions of the invention may also contain antigens other than Norovirus or Sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases, such as antigens derived from rotavirus. | 2010-11-18 |
20100291130 | CLONED GENOME OF INFECTIOUS HEPATITIS C VIRUS STRAIN HC-TN AND USES THEREOF - Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1a, proteins and polypeptides and fragments thereof. Use of these compositions, and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV are also contemplated. | 2010-11-18 |
20100291131 | CLOSTRIDIAL TOXIN NETB - The present invention relates to a polypeptide based toxin that originates from | 2010-11-18 |
20100291132 | Streptococcus uberis adhesion molecule - A polypeptide, designated as “ | 2010-11-18 |
20100291133 | RECOMBINANT PROTEIN CONTAINING A C-TERMINAL FRAGMENT OF PLASMODIUM MSP-1 - The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the | 2010-11-18 |
20100291134 | TRUNCATED HEPATITIS C VIRUS NS5 DOMAIN AND FUSION PROTEINS COMPRISING SAME - The invention provides truncated HCV NS5 polypeptides and fusion proteins comprising the truncated NS5 polypeptides, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4 | 2010-11-18 |
20100291135 | Species of fungi and their use in pest and disease control - The present invention describes substantially pure cultures of three new species of fungi, | 2010-11-18 |
20100291136 | Pharmaceutical Liquid Composition of Botulinum Toxin With Improved Stability - Disclosed herein is a liquid pharmaceutical composition of | 2010-11-18 |
20100291137 | METHOD FOR REFOLDING NEISSERIAL NSPA PROTEIN - The present invention provides an isolated refolded NspA protein, and a method of preparing it. | 2010-11-18 |
20100291138 | Vaccine - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen form | 2010-11-18 |
20100291139 | RECOMBINANT MVA VIRUS AND THE USE THEREOF - The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines. | 2010-11-18 |
20100291140 | ANTIBIOTIC RESISTANCE FREE LISTERIA STRAINS AND METHODS FOR CONSTRUCTING AND USING SAME - The present invention provides | 2010-11-18 |
20100291141 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 11 - The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections. | 2010-11-18 |
20100291142 | Bacterial Artificial Chromosome Containing Feline Herpes Virus Type 1 Genome and Uses Thereof - The present invention relates to recombinant feline herpes virus type 1 (FHV-1) nucleic acids and proteins. In particular the present invention provides compositions comprising the full length FHV-1 genome or portions thereof, and infectious FHV-1 virions produced therefrom. The FHV-1 compositions are suitable for use in inducing an immune response in inoculated subjects and for use in identifying agents that attenuate FHV-1 infection. | 2010-11-18 |
20100291143 | Inhibition of HIV and SHIV Replication with Antisense Interleukin-4 - A method of treating or preventing SHIV or HIV infection in a subject comprising administering a therapeutically effective amount of a antisense IL-4. The antisense IL-4 inhibits viral replication in the liver, lungs, spleen, and even the lymph nodes of the subject. Further, the antisense IL-4 can be used in combination with other antiretroviral agents or vaccines. | 2010-11-18 |
20100291144 | NOVEL VACCINES AGAINST MULTIPLE SUBTYPES OF DENGUE VIRUS - An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal. | 2010-11-18 |
20100291145 | Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES - Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope, or said encoded protein or peptide. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide, or said encoded protein or peptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less. | 2010-11-18 |
20100291146 | METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST PANDEMIC INFLUENZA VIRUS - A method for eliciting or inducing a protective immune response in a subject against a pandemic subtype of influenza virus comprises administering to the subject a composition comprising (i) at least one immunogen of an endemic influenza subtype, and (ii) an immunogen-free immunostimulating complex as adjuvant. | 2010-11-18 |
20100291147 | RECOMBINANT RSV ANTIGENS - This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection. | 2010-11-18 |
20100291148 | Shigella mutants in the functions pertaining to the processes of maturing and recycling peptidoglycans and their uses as immunogens - Bacteria belonging to the | 2010-11-18 |
20100291149 | ATTENUATED LISTERIA SPP. AND METHODS FOR USING THE SAME - Attenuated | 2010-11-18 |
20100291150 | PSEUDOMONAS EXOTOXIN A CD4+ T-CELL EPITOPES - The present invention provides PE CD4+ T-cell epitopes, as well as novel variants that exhibit reduced immunogenic responses, as compared to the parental PE. The present invention further provides DNA molecules that encode novel PE variants, host cells comprising DNA encoding novel PE variants, as well as methods for making PEs less immunogenic. In addition, the present invention provides various compositions that comprise these PE variants that are less immunogenic than wild-type PEs. | 2010-11-18 |
20100291151 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR - The present invention relates to new 1-methylpyrazole modulators of substance P release, calcitonin gene-related peptide activity, adrenergic receptor activity, and/or 5-HT receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-11-18 |
20100291152 | CHEMICALLY MODIFIED PEPTIDES WITH IMPROVED IMMUNOGENICITY - The invention provides processes for improving the ability of a peptide to stimulate an immune response, comprising exposing the peptide to a chemical modifying agent. It further provides compositions comprising an antigenic peptide, wherein the peptide has been treated with a chemical modifying agent to improve its ability to stimulate an immune response. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a vaccine. | 2010-11-18 |
20100291153 | VACCINES AGAINST BORDETELLA PERTUSSIS BASED ON LPS GLYCOSYLTRANSFERASE MUTANTS - The invention relates to an improved vaccine against | 2010-11-18 |
20100291154 | COMPOSITION FOR INHIBITION OF TRANSPLANT REJECTION CONTAINING THE CORDYCEPS MYCELLIA EXTRACT AS AN ACTIVE INGREDIENT - Disclosed is a composition for the inhibition of transplant rejection and the prevention and treatment of skin diseases, comprising a | 2010-11-18 |
20100291155 | ALLERGY VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION - The present invention relates to an allergy vaccine composition for mucosal administration comprising a cysteine protease allergen in a reduced active state or in an oxidised inactive state, The inventions further relates to an adjuvant system for use in a vaccine for mucosal administration comprising a cysteine protease. | 2010-11-18 |
20100291156 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) - The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine. | 2010-11-18 |
20100291157 | COMPOSITION FOR HEADACHE TREATMENT - A nutritional composition for treating severe headaches and comprising a plurality of vitamins and a plurality of minerals that together represent at least a portion of required daily allowance thereof. The plurality of vitamins include at least vitamins A, C, D, E, K, B-1, B-2, B-6, and B-12, niacin, folic acid, biotin, pantothenic acid, and mixtures thereof, while the plurality of minerals include at least selenium, zinc, magnesium, calcium, iron, manganese, copper, chromium, cobalt, phosphorous, iodine, potassium and molybdenum. The composition further includes at least one or both of 125-175 mg of co-enzyme Q-10 and 25-150 mg of purified Butterbur root extract. | 2010-11-18 |
20100291158 | SUSTAINED RELEASE ORAL COMPOSITION OF AN ANTIPSYCHOTIC AGENT - A sustained release oral composition of an antipsychotic agent comprising antipsychotic agent, λ-carrageenan and one or more pharmaceutically acceptable excipients; wherein the antipsychotic agent is 2-[2-(4-dibenzo{b,f}[1,4-thiazepin-11yl-1-piperazinyl)ethoxy ethanol] or its pharmaceutically acceptable salt. | 2010-11-18 |
20100291159 | FILM COATINGS CONTAINING FINE PARTICLE SIZE DETACKIFIERS AND SUBSTRATES COATED THEREWITH - The present invention is directed to film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain a fine particle size detackifier. The film coating compositions can be applied either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the polymer is either polyvinyl alcohol or a copolymer of polyvinyl alcohol. Aqueous suspensions comprising the inventive film coating compositions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed. | 2010-11-18 |
20100291160 | PHARMACEUTICAL SYSTEM FOR TRANS-MEMBRANE DELIVERY - Non-invasive drug delivery systems useful for the absorption of therapeutically active agents through the epithelial membrane are described. The non-invasive drug delivery system delivers a therapeutic active agent with an ionizable, or ionized, metal, transition metal or metal-containing vehicle. The non-invasive drug delivery system may also have a pH adjustable vehicle which facilitates the absorption of the therapeutic agents by altering the pH of the non-invasive drug delivery system at the site of administration. Also disclosed is a method for the pH “sweeping” of the administered therapeutic active agent to provide a consistent and reproducible absorption of the active agent. Certain formulations utilize low doses of active agents without altering the active agents from their current or previous form. | 2010-11-18 |
20100291161 | CELLULOSE POWDER - Cellulose powder having an especially excellent balance among moldability, fluidity and disintegrating property is provided. Cellulose powder having an average polymerization degree of 150-450, an average L/D (the ratio of the major axis to the minor axis) value of particles of 75 μm or less of 2.0-4.5, an average particle size of 20-250 μm, an apparent specific volume of 4.0-7.0 cm | 2010-11-18 |
20100291162 | ORAL COMPOSITIONS PROVIDING ENHANCED TOOTH STAIN REMOVAL - This invention generally relates to oral compositions (e.g., a confection or chewing gum product such as a compressed chewing gum) effective for removal of stains from a tooth surface. In particular, this invention relates to oral compositions including a coated or an encapsulated protease enzyme to provide an oral composition effective for tooth stain removal. | 2010-11-18 |
20100291163 | ORAL CARE COMPOSITION COMPRISING NANOPARTICULATE TITANIUM DIOXIDE - The present invention relates to an oral care composition comprising nanoparticulate titanium dioxide, optionally together with a source of fluoride ions, for combating dental erosion and/or tooth wear. In addition such compositions may also have benefit in tooth whitening. When a source of fluoride ions is present such compositions are also of benefit in combating dental caries. | 2010-11-18 |
20100291164 | FUNCTIONALIZED CALCIUM PHOSPHATE HYBRID SYSTEMS FOR THE REMINERALIZATION OF TEETH AND A METHOD FOR PRODUCING THE SAME - A dental remineralizing system, including a functionalized calcium-containing complex having an organic surfactant component mechanochemically attached to a distressed calcium phosphate component and blended with the comestible material. | 2010-11-18 |
20100291165 | PERSONAL CARE COMPOSITION IN THE FORM OF AN ARTICLE HAVING A HYDROPHOBIC SURFACE-RESIDENT COATING - The present invention relates to personal care compositions, especially those personal care compositions in the form of an article that is a porous, dissolvable solid structure. The article has a hydrophobic surface-resident coating that can provide enhanced deposition efficiency of hydrophobic actives contained therein. | 2010-11-18 |
20100291166 | USE OF NITROGEN-DOPED TITANIUM OXIDE NANOPARTICLES AS AGENTS FOR PROTECTING AGAINST ULTRAVIOLET RADIATION - A nanometric material includes nitrogen-doped titanium oxides, which is obtained by injection of a titanium oxide precursor in the liquid or gaseous form and of a gaseous nitrogenous compound into a laser pyrolysis reactor. The material is used as cosmetic agent for protecting against ultraviolet radiation, thereby improving protection against UV radiation and in particular against UV-A radiation. | 2010-11-18 |
20100291167 | POROUS CARBON MATERIAL COMPOSITES AND THEIR PRODUCTION PROCESS, ADSORBENTS, COSMETICS, PURIFICATION AGENTS, AND COMPOSITE PHOTOCATALYST MATERIALS - Provided is a porous carbon material composite formed of a porous carbon material and a functional material and equipped with high functionality. A porous carbon material composite is formed of (A) a porous carbon material obtainable from a plant-derived material having a silicon (Si) content of 5 wt % or higher as a raw material, said porous carbon material having a silicon (Si) content of 1 wt % or lower, and (B) a functional material adhered on the porous carbon material, and has a specific surface area of 10 m | 2010-11-18 |
20100291168 | ANTIMICROBIAL FORMULATIONS COMPRISING A COMBINATION OF A PYRIDINE THIOL AND A BIS-QUINOLINIUM SALT - An antimicrobial formulation containing a pyridine thiol and a bis-quinolinium salt which contains a cation of formula (I) below: wherein n is an integer from 3 to 18. The formulation may in particular be used for the treatment of a bacterial condition, more particularly acne or body odour. It is suitably applied topically. | 2010-11-18 |
20100291169 | Polyelectrolyte Complex for Imparting Antimicrobial Properties to a Substrate - Anionic polyelectrolytes are used as binding agents to reduce the solubility of cationic antimicrobial polyelectrolytes. Ionic attraction between the anionic stabilizing polyelectrolytes and the antimicrobial cationic polyelectrolytes results in formation of a polyelectrolyte complex (PEC). A treatment liquid comprising a stable colloid, suspension, dispersion, solution, coacervate, or emulsion of the PEC in an aqueous carrier is used to treat an article, thus coating, infiltrating, or infusing the PEC onto or into the article. Subsequent drying results in an antimicrobial article wherein the PEC is bound to the article and is significantly less prone, relative to either of the component polyelectrolytes, to being washed, leached, leaked, extracted, or migrated from the antimicrobial article during use, or when exposed to aqueous fluids or solvents. The antimicrobial article can be further treated with ethylene oxide which enhances its antimicrobial efficacy, its biocompatibility, and its utility in wound dressings, medical devices, clothing, etc. | 2010-11-18 |
20100291170 | NOVEL THERAPIES FOR CHRONIC RENAL FAILURE - The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins. | 2010-11-18 |
20100291171 | HYALURONIC ACID DERIVATIVES OBTAINED VIA "CLICK CHEMISTRY" CROSSLINKING - Crosslinked derivatives of polycarboxylated polysaccharides are described, wherein at least one of the polysaccharide chains consists of hyaluronic acid or a derivative thereof, crosslinked by means of reactions of the “click chemistry” type and their use in the field of viscosupplementation, plastic surgery, oncologic and reconstructive surgery and also as matrices for controlled release systems of biologically and/or pharmacologically active molecules and/or macromolecules. | 2010-11-18 |
20100291172 | Sterile Autologous, Allogenic or Xenogenic Implant and the Method of its Production - The subject of the invention is a sterile, dehydrated acellular implant, which during its rehydration by water or bodily fluids displays anisotropic expansion and can act as a substrate for adhesion, migration and growth of live cells. Collagen structures of the transplant are at least partially denatured through the action of heat or organic solvents, such as lower aliphatic alcohols and ketones, which simultaneously act as preservative and sterilization agents, especially for certain types of viruses. The implant is sterilized by radiation while in an substantially dehydrated state, preferably by accelerated electrons. The transplant can be derived from various animal tissues, especially mammalian tissues, such as human or porcine tissues. The tissues suitable for the invention can be, for example, skin, placenta, pericardium, peritoneum, intestinal wall, tendon, blood vessel, etc. The implant is suitable for use in human and veterinary medicine, for instance as a temporary wound and burn cover, for the repair, substitution and regeneration of tissues, and also as a substrate for laboratory cell cultivation. | 2010-11-18 |
20100291173 | METHOD OF IMPROVING RENAL FUNCTION - A method of improving renal function in a mammal suffering from, or at risk of developing, at least partial renal failure or renal dysfunction, includes administering to renal tissue of the mammal, a combination comprising a non-viral vector comprising a non-viral particulate carrier which carries a therapeutically effective amount of genetic material capable of expressing a renal function-enhancing Osteogenic Protein-1/Bone Morphogenic Protein-7 (OP-1/BMP-7) polypeptide in the renal tissue. | 2010-11-18 |
20100291174 | BIOLOGICALLY ACTIVE DEVICE AND METHOD FOR ITS PRODUCTION - The present invention is directed to a biologically active device with a main body made from a polymer, in which bioactive nanoparticles of one or several materials are embedded, wherein the nanoparticles of at least one material proliferatively act on a biological material contacted by the device, and wherein nanoparticles of a different material act in an anti-proliferative manner on biological material in the ambience of the device. The invention is also directed to a method of manufacturing a biologically active device with a main body made from a polymer, wherein nanoparticles of several different materials are dispersed in an injection-moldable fluid, and the fluid is shaped into the polymer main body by means of injection molding and curing, such that the nanoparticles are dispersed in the bulk of the polymer main body. According to the invention, the nanoparticles are generated by arranging at least two substrates of different material in a vessel filled with a fluid material, and by generating the nanoparticles by abrasion from the surface of the substrates in the fluid with laser radiation. | 2010-11-18 |
20100291175 | POLYMERS COMPRISING AMORPHOUS TERPOLYMERS AND SEMICRYSTALLINE BLOCKS - The present invention provides an implantable article comprising an amorphous terpolymer and a semi-crystalline polymer. The amorphous terpolymer can be admixed with the semi-crystalline polymer or form a block copolymer with the semi-crystalline polymer. | 2010-11-18 |
20100291176 | MANUFACTURING THREE-DIMENSIONAL SCAFFOLDS USING CRYOGENIC PROTOTYPING - The present invention refers to a method of fabricating a three dimensional scaffold suitable for tissue-engineering having a controlled micro- and macroporous structure using cryogenic prototyping. The present invention also refers to scaffolds obtained by the method of the present invention and to their use. | 2010-11-18 |
20100291177 | PREVENTION OF STAPHYLOCOCCUS BIOFILM FORMATION - The present application discloses antibodies directed to protein SE2232 (SesC) of | 2010-11-18 |
20100291178 | Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue of bone - Methods and apparatuses are provided for musculoskeletal tissue engineering. For example, a scaffold apparatus is provided which comprises microspheres of selected sizes and/or composition. The microspheres are layered to have a gradient of microsphere sizes and/or compositions. The scaffold provides a functional interface between multiple tissue types. | 2010-11-18 |
20100291179 | COMPOSITE BIOMATERIAL FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS - The present invention relates to a composite biomaterial and a process for producing a composite biomaterial with controlled release of active ingredients, comprising a three-dimensional polymer-based support structure, and a polymer-based matrix structure. The active ingredients are in this case incorporated into the composite biomaterial via the matrix structure, and the composite biomaterial is obtainable by introducing the matrix structure into the support structure. The active ingredients may in this case be incorporated for example adhesively, via specific binder molecules or via enzyme-labile linker molecules via the matrix structure into the composite biomaterial. | 2010-11-18 |